all report title image

EMBOLIZATION PARTICLE MARKET ANALYSIS

Embolization Particle Market, by Product type (Radioembolization Spheres, Microspheres, Drug Eluting Beads, PVA Particles & Gelfoam Particles, and Other Particles), by Application (Peripheral Vascular Disease, Neurology, Oncology, Urology, and Others), by End User (Hospitals & Clinics, Ambulatory Centers, and Others) and by Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) — Size, Share, Outlook, and Opportunity Analysis, 2022-2028

  • To Be Published : Dec 2024
  • Code : CMI2374
  • Formats :
      Excel and PDF
  • Industry : Medical Devices

Embolization Particle MarketSize and Trends

Embolization Particle Market - Market Dynamics

The market for embolization particle is driven by factors such as increasing prevalence of various types of cancer.  

Embolization particles are the crucial product used in the treatment of malignancies such as cancer, peripheral diseases, and others. Rising prevalence of cancer globally, has supported growth of the embolization particle market. According to World Health Organization (WHO), cancer is the second prominent cause of death across the globe, and around 9.6 million deaths occurred due to cancer in 2018. Moreover, as per the Cancer Research UK, over 17 million new cases were estimated to occur in year 2018 around the globe. The burden of cancer is increasing rapidly in the U.S. with the incidence of 439.2 per 100,000 men and women per year as according to National Cancer Institute (2015).

Moreover, major players are constantly introducing technologically advanced products with improved efficiency that supports growth of the embolization particle market. For instance, in 2017, Sirtex introduced SIR-Spheres Y-90 resin microspheres, which serves as first-line treatment for patients with liver metastases from right-sided primary colon cancer. In 2016, UK National Institute for Health and Care Excellence (NICE) issued a new update stating that National Health Service (NHS) doctors and commissioners may consider Sirtex’s SIR-Spheres Y-90 resin microspheres as an alternative to standard therapy with trans-arterial chemoembolization (TACE) or sorafenib in the treatment of patients with inoperable primary liver cancer.

Market Trends

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.